1 active not recruiting, 1 recruiting, 1 unknown. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 1, Recruiting 1, Unknown 1 |
Follow mFOLFOX6 regimen: new trials by email Literature Review of mFOLFOX6 regimen trials Research Report on mFOLFOX6 regimen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 3 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 204 | 2026-05-20 | 2026-07-01 |
| Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) MRTX849, Cetuximab, mFOLFOX6 Regimen - Advanced Colorectal Cancer, Metastatic Colorectal Cancer | Phase 3 | Active not recruiting | Mirati Therapeutics Inc. | 461 | 2021-06-24 | 2026-09-28 |
| QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety QL1203, Placebo, mFOLFOX6 regimen - Metastatic Colorectal Cancer | Phase 3 | Unknown | Qilu Pharmaceutical Co., Ltd. | 590 | 2020-01-20 | 2023-05-26 |
Colorectal Neoplasms (2) · Rectal Neoplasms (2) · Colonic Neoplasms (1)
Mirati Therapeutics Inc. (1) · Qilu Pharmaceutical Co., Ltd. (1) · Sixth Affiliated Hospital, Sun Yat-sen University (1)
China (3) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · Colombia (1) · Czechia (1) · Denmark (1) · Finland (1) · France (1) · Germany (1) · Greece (1) · Hong Kong (1)
Jun Huang, PhD (1) · Lin Shen, Professor (1) · Weijian Guo, Professor (1)